Author:
Mak David Y.,Tjong Michael C.,Louie Alexander V.
Subject
Pulmonary and Respiratory Medicine,Oncology
Reference5 articles.
1. Randomized phase 2 study of osimertinib plus bevacizumab versus osimertinib for untreated patients with nonsquamous NSCLC harboring EGFR mutations: WJOG9717L study;Kenmotsu;J Thorac Oncol,2022
2. Wang XS, Bai YF, Verma V, et al. Randomized trial of first-line tyrosine kinase inhibitor with or without radiotherapy for synchronous oligometastatic EGFR-mutated NSCLC [e-pub ahead of print]. J Natl Cancer Inst. https://doi.org/10.1093/jnci/djac015, accessed October 8, 2022.
3. An especially high rate of radiation pneumonitis observed in patients treated with thoracic radiotherapy and simultaneous osimertinib;Jia;Radiother Oncol,2020
4. Pulmonary toxicity after bevacizumab and concurrent thoracic radiotherapy observed in a phase I study for inoperable stage III non-small-cell lung cancer;Lind;J Clin Oncol,2012
5. Safety and tolerability of metastasis-directed radiation therapy in the era of evolving systemic, immune, and targeted therapies;Guimond;Adv Radiat Oncol,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献